Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $123.35. The company's market cap stands at 153.71B, with a P/E ratio of 19.26 and a dividend yield of 2.5%.
On 2025-12-03, Gilead Sciences(GILD) stock traded between a low of $123.35 and a high of $125.08. Shares are currently priced at $123.35, which is 0.0% above the low and -1.4% below the high.
The Gilead Sciences(GILD)'s current trading volume is 5.11M, compared to an average daily volume of 7.15M.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
GILD News
Gilead Sciences Inc (Symbol: GILD) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-averagestatistic...
Gilead Sciences recently delivered its first shipments of the injectable HIV prevention drug lenacapavir to Eswatini and Zambia, advancing efforts to expand acc...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...
Analyst ratings
71%
of 31 ratingsMore GILD News
Wondering if Gilead Sciences is actually a bargain or overpriced right now? You are not alone, especially with so much chatter about the company's future outloo...